• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP TERUFLEX BLOOD BAG SYSTEM; TERUFLEX QUADRUPLE BLOOD BAG 500ML COLLECTION BAGS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP TERUFLEX BLOOD BAG SYSTEM; TERUFLEX QUADRUPLE BLOOD BAG 500ML COLLECTION BAGS Back to Search Results
Catalog Number 1BBWGQ506A2
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 01/11/2023
Event Type  malfunction  
Manufacturer Narrative
Investigation: the sets concerned have not yet been provided for evaluation.We therefore conducted investigations based on the provided information in making the blood bags concerned, sealed bags are filled with solution and the line is assembled.These bags are sterilized, stacked, and placed into the blister packs.The top film of each blister pack is heat-sealed.In making leukoreduction filters, filter membranes are formed and put in filter housings.We reviewed the manufacturing record of the lot number in question.There was no equipment trouble causing the issue concerned and we confirmed that the equipment had operated properly, and no anomalies had been observed.We also reviewed the manufacturing records regarding particulate removal rates of filter membranes that were likely to be related to filtration performance.It was confirmed that all filter membranes conformed to all standards.Release testing, which includes measurements of solution concentration and volume and a visual inspection, is performed on the product concerned on a sample basis.We reviewed each testing and inspection record of the production number and confirmed that there were no anomalies in all release testing items.The product conformed to the standards.We visually inspected three sets of our retained samples of the lot number concerned.There were no abnormalities in their appearances.We used these sets to measure the solution volume and also to perform the quantitative test for the composition of the solution in the same manner as the release testing.The results conformed to our in-house standards.Root cause: from the above-mentioned investigation results, we did not observe any abnormalities in the manufacturing process of the lot number concerned.Leukoreduction failure is commonly caused by the following factors: 1) blood characteristics of donors there is a possibility of leukoreduction failure due to blood characteristics of donors.2) pressure loaded on filter membranes for some reason, where a physical stress on filter membranes is greater than what is expected, trapped white blood cells are pushed out of the filter membranes and may result in leukoreduction failure.For the prevention of leukoreduction failure, the instructions for use (ifu) of the product state: "[caution] do not squeeze or apply pressure on the filter while it is attached to the bag containing the filtered blood".Based on the investigation results of similar issues which we received in the past, a general cause of leukocyte reduction failure can be cited that pressure was applied to the collection bag or the filter during the filtration process of the collected blood.We confirmed in some complaints previously reported that the following cases caused leukoreduction failure.- blood was filtered within 30 minutes after blood collection.- the tube below the filter was not clamped before blood flowed into the filter when expelling air.
 
Event Description
The customer would like the run data file investigated to determine a possible cause for the elevated white blood cell (wbc) content in the platelet product.There was not a transfusion recipient or patient involved at the time of the residual wbc testing, therefore no patient information is reasonably known at the time of the event.Terumo bct is awaiting return of the disposable set for evaluation.
 
Manufacturer Narrative
This report is being filed to provide corrected information in investigation: the sets were not provided by the customer for evaluation.We therefore conducted investigations based on the provided information.In making the blood bags concerned, sealed bags are filled with solution and the line is assembled.These bags are sterilized, stacked, and placed into the blister packs.The top film of each blister pack is heat-sealed.In making leukoreduction filters, filter membranes are formed and put in filter housings.We reviewed the manufacturing record of the lot number in question.There was no equipment trouble causing the issue concerned and we confirmed that the equipment had operated properly, and no anomalies had been observed.We also reviewed the manufacturing records regarding particulate removal rates of filter membranes that were likely to be related to filtration performance.It was confirmed that all filter membranes conformed to all standards.Release testing, which includes measurements of solution concentration and volume and a visual inspection, is performed on the product concerned on a sample basis.We reviewed each testing and inspection record of the production number and confirmed that there were no anomalies in all release testing items.The product conformed to the standards.We visually inspected three sets of our retained samples of the lot number concerned.There were no abnormalities in their appearances.We used these sets to measure the solution volume and also to perform the quantitative test for the composition of the solution in the same manner as the release testing.The results conformed to our in-house standards.Root cause: from the above-mentioned investigation results, we did not observe any abnormalities in the manufacturing process of the lot number concerned.Leukoreduction failure is commonly caused by the following factors: 1) blood characteristics of donors there is a possibility of leukoreduction failure due to blood characteristics of donors.2) pressure loaded on filter membranes for some reason, where a physical stress on filter membranes is greater than what is expected, trapped white blood cells are pushed out of the filter membranes and may result in leukoreduction failure.For the prevention of leukoreduction failure, the instructions for use (ifu) of the product state: "[caution] do not squeeze or apply pressure on the filter while it is attached to the bag containing the filtered blood".Based on the investigation results of similar issues which we received in the past, a general cause of leukocyte reduction failure can be cited that pressure was applied to the collection bag or the filter during the filtration process of the collected blood.We confirmed in some complaints previously reported that the following cases caused leukoreduction failure.- blood was filtered within 30 minutes after blood collection.- the tube below the filter was not clamped before blood flowed into the filter when expelling air.
 
Event Description
The customer would like the run data file investigated to determine a possible cause for the elevated white blood cell (wbc) content in the platelet product.There was not a transfusion recipient or patient involved at the time of the residual wbc testing, therefore no patient information is reasonably known at the time of the event.The disposable set is not available for return because it was discarded by the customer.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TERUFLEX BLOOD BAG SYSTEM
Type of Device
TERUFLEX QUADRUPLE BLOOD BAG 500ML COLLECTION BAGS
Manufacturer (Section D)
TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP
fujinomiya
JA 
Manufacturer (Section G)
TERUMO CORPORATION, FUJINOMIYA FACTORY OF TERUMO CORP
818 misonodaira
fujinomiya 418-0 004
JA   418-0004
Manufacturer Contact
makoto yoshikawa
818 misonodaira
fujinomiya 418-0-004
JA   418-0004
MDR Report Key16294736
MDR Text Key309508215
Report Number9681839-2023-00006
Device Sequence Number1
Product Code CAK
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 02/03/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number1BBWGQ506A2
Device Lot Number220222AF
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 01/11/2023
Initial Date FDA Received02/03/2023
Supplement Dates Manufacturer Received03/16/2023
Supplement Dates FDA Received03/24/2023
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-